Acta Med. Okayama, 2007
Vol. 61, No. 4, pp. 181-189
Copyright©2007 by Okayama University Medical School.

Acta Medica Okayama
http://www.lib.okayama-u.ac.jp/www/acta/

Review

Biomarkers of Oxidative/Nitrosative Stress: An Approach to Disease Prevention

Keiki Ogino* and Da-Hong Wang

Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

Oxidative/nitrosative stress is responsible for a variety of degenerative processes in some human diseases. Measurement of oxidatively/nitrosatively modified DNA, proteins, lipids, and sugars in biological samples has been expected to detect appropriate biomarkers for diseases in which reactive oxygen/nitrogen species are involved. Recently, the application of these biomarkers to epidemiological studies has resulted in a new discipline, molecular epidemiology, which provides the opportunity for better understanding of their causal relation with disease outcomes in a population level. In this brief review, we cover some specific biomarkers of oxidative/nitrosative stress with regard to the commonly used analytical methods for these biomarkers, their integration with epidemiology, and their application in antioxidant intervention trials, with an emphasis on those applicable to human studies and their potentialities for disease prevention.

Key words: biomarker, oxidative/nitrosative stress, molecular epidemiology, disease prevention

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced as by-products of normal metabolic processes in all aerobic organisms. In physiological conditions, the antioxidant defense systems in the body protect the cells and tissues against these species [1]. When the generation of ROS/RNS exceeds the ability of antioxidant defense systems to remove them, such an imbalance can cause oxidative/nitrosative damage to cellular constituents (DNA, proteins, lipids, and sugars), which is defined as oxidative/nitrosative stress [1, 2]. Many studies have shown that oxidative/nitrosative stress is responsible for a variety of the degenerative processes of some human diseases [1, 3]. Since ROS/RNS themselves are very reactive and have an extremely short half-life, direct determination of them in tissue or body fluids is generally impracticable. Therefore, measurement of oxidatively/nitrosatively modified DNA, proteins, lipids, and sugars in biological samples has been expected to detect appropriate biomarkers for diseases in which ROS/RNS are involved.

The National Academy of Sciences in the United States defines biomarkers as “indicators, signaling events in biological systems or samples” [4]. The biomarkers can be used as “intermediate endpoints or early-outcome predictors” of disease development for preventive purposes [5]. Recently, there has been a great improvement in assay methods and measurement accuracy for biomarkers of oxidative/nitrosative

Received October 17, 2006; accepted January 16, 2007.
*Corresponding author. Phone: +81-86-235-7184; Fax: +81-86-226-0715
E-mail: kogino@md.okayama-u.ac.jp (K. Ogino)

stress [6, 7], and the incorporation of biomarkers into epidemiological studies provides a promising field for better understanding the role of ROS/RNS in the pathogenesis and progression of diseases. In this brief review we cover some specific biomarkers of oxidative/nitrosative stress, with an emphasis on those applicable to human studies and their potentialities for disease prevention.

Biomarkers of Protein Oxidation/Nitration

Protein carbonyls. Protein carbonyl groups are generated by direct oxidation of amino acid residues, particularly lysine, arginine, threonine, and proline (Fig. 1), or by secondary reaction with the primary oxidation products of sugars and lipids [7-9]. Such oxidative modifications of proteins result in important changes in the proteins' structure and function. Several studies have proved that proteins are major initial cell targets of ROS, leading to earlier formation of the protein carbonyls in biological systems [10-12], and detection of increased levels of protein carbonyls has been proposed as "a sign of disease-associated dysfunction" [13]. Patients with neurodegenerative illnesses [14], diabetes and hypercholesterolemia [15], and children with juvenile chronic arthritis [16] were found to have elevated levels of total protein carbonyls, suggesting the potentiality of carbonated proteins serving as biomarkers for early diagnosis of these diseases.

Protein carbonyls are widely used and chemically stable biomarkers of oxidative stress. They circulate for longer periods in the blood compared to other oxidized products [17], and the assay sample can be kept at -80 °C for at least 10 years [18]. For detection of carbonylated proteins in human diseases, the commonly employed methods are spectrophotometric 2,4-dinitrophenylhydrazine (DNPH) assay, spectrophotometric DNPH assay coupled to protein fractionation by HPLC, and one- or two-dimensional electrophoresis and Western blot immunoassay [7, 19]. However, these methods cannot identify which amino-acid residues are oxidatively attacked and which protein has been modified [1]. Recently, the proteomics technique, which allows one to identify specific carbonated proteins in the plasma and hippocampus of subjects with Alzheimer's disease, has thrown new light on this issue [20, 21]. The proteomics technique mainly consists of two-dimensional gel electrophoresis for protein separation and mass spectrometry for protein identification; this technique may allow researchers to develop a specific intervention strategy for this disease.

Nitration of tyrosine. The 3-nitrotyrosine (Fig. 1) generated by nitration of the amino acid tyrosine and protein-bound tyrosine is another biomarker for studying the *in vivo* oxidation/nitration of protein [22]. There is considerable evidence in the literature that elevated levels of 3-nitrotyrosine occur in diseases associated with ROS/RNS. Mean plasma levels

1. Biomarkers of protein oxidation/nitration



2. Biomarkers of DNA oxidation/nitration



3. Biomarkers of lipid oxidation



4. Oxidative modification of sugars (AGEs)



Fig. 1 Chemical structures of some examples of biomarkers.

of nitrotyrosine are significantly higher in diabetic patients with lower intake of some antioxidant vitamins (vitamin A, C) and positively correlated with serum fasting glucose [23], and are also higher in patients with coronary artery disease and modulated by statin therapy [24]. Taken together, these results imply that plasma nitrotyrosine measurement in humans is possibly a useful tool for monitoring the effect of antioxidant intervention. In a controlled weight loss trial, weight reduction was strongly associated with a decrease in serum protein 3-nitrotyrosine levels in Caucasian women but not in African-American women [25].

The 3-nitrotyrosine in biological samples has been detected and quantified by a variety of methods. Antibody-based methods {enzyme-linked immunosorbent assay (ELISA)} are considered to be semiquantitative because there is no strict assay validation and it is difficult to assess the tests' reliability [7]. HPLC with electrochemical detection (ECD), mass spectrometry-based assays {gas chromatograph-mass spectrometry (GC-MS) and gas chromatograph-tandem mass spectrometry (GC-MS/MS), liquid chromatograph-mass spectrometry (LC-MS) and liquid chromatograph- tandem mass spectrometry (LC-MS/MS)} are proposed to have adequate sensitivity for quantification of 3-nitrotyrosine, especially the use of MS/MS technique can remove interference caused by the coelution of substances in GC-MS [7]. However, recent reviews have raised concerns about the quantification of circulating 3-nitrotyrosine in human plasma because of the varied plasma levels of both free and protein-bound 3-nitrotyrosine in healthy subjects in reported findings [26, 27]. More efforts are needed to improve the methodology for measurement of 3-nitrotyrosine *in vivo*, particularly at low concentrations, and standardization of nitrotyrosine measurements is probably needed to make comparisons possible among studies [26, 27]. Shishehbor *et al.* found that protein-bound nitrotyrosine values in plasma determined by isotope-dilution LC-tandem MS are reproducibly greater than that in serum and are stable over time in healthy subjects [24]. In addition, great care should be taken during sample preparation and analysis because the artifactual formation of nitrotyrosine during sample processing, especially under acidic conditions, can confound nitrotyrosine determinations [26].

The results of several studies have demonstrated the successful detection of 3-nitrotyrosine-containing proteins *in vivo* using a qualitative proteomics approach [28–30], by which a total of 48 and 11 putative proteins containing nitrotyrosine in heart and skeletal muscle of aged rats were identified, respectively [31, 32], and 40 nitrotyrosine-immunopositive proteins were also identified in both rat tissue extract and cell culture inflammatory disease models [28]. This promising approach may offer an early diagnostic tool for disease by defining patterns of abnormal proteins [33].

Biomarkers of DNA Oxidation/Nitration

8-hydroxy-2'-deoxyguanosine. Elevated levels of oxidatively modified DNA lesions are considered responsible for an increased risk of cancer development later in life [34]. The most representative product that may reflect oxidative damage to DNA in the cells is 8-hydroxy-2'-deoxyguanosine (8-OHdG) (Fig. 1), a product of oxidatively modified DNA base guanine [1]. Elevated levels of 8-OHdG have been found in the serum and myocardium of patients with heart failure [35] and in the urine of patients with Parkinson's disease [36]. Many methods such as HPLC-ECD, GC-MS, LC-MS, and immunoassay have been established to measure 8-OHdG in biological specimens and are reviewed in detail in several articles [6, 37, 38].

HPLC-ECD is a frequently used method with high accuracy and sensitivity, but the procedures are complex and time-consuming [6]. Measurement of low levels of oxidative DNA damage is still an issue for GC-MS and HPLC-tandem MS [38]. Isotope-dilution LC-tandem MS has been proposed as a highly specific and sensitive analytical method for urinary 8-OHdG in human subjects [39]. Immunohistochemistry is also a popular method with good sensitivity and simplicity, but it can only semiquantitatively measure 8-OHdG [37]. Two commercially available kits are used; the one using monoclonal antibody N45.1 is from the Japan Institute for the Control of Aging (Fukuroi, Shizuoka, Japan), and the other using monoclonal antibody clone 1F7 is from Trevigen (Gaithersburg, MD, USA) [40]. The 2 showed a strong correlation ($r = 0.9$), although the latter demonstrated 3 times higher urinary values, in which not only 8-OHdG but

also 8-hydroxyguanosine (8-OHG: analogue of 8-OHdG derived from RNA) and 8-hydroxyguanine (8-OHGua: an oxidatively modified free guanine base) were included [40]. None of the available methods for measuring 8-OHdG formation can locate the original site of oxidative DNA damage [37].

The measurement of urinary 8-OHdG has been considered to reflect the whole-body oxidative DNA damage [37], and the correlation coefficient of 8-OHdG measurements between spot and 24 h urine samples is 0.50 (by HPLC) and 0.87 (by ELISA), respcetively [41]. The level of urinary 8-OHdG was found to be independent of dietary influence in humans [42], although that was not the case in rats [43].

8-nitroguanine. It is known that RNS such as oxides of nitrogen (NO_X) and peroxynitrite ($ONOO^-$) generated in various pathophysiological conditions can nitrate guanine and its related nucleosides and nucleotides in the free form or in DNA/RNA [44]. The 8-nitroguanine (Fig. 1) is a representative DNA nucleobase product of nitrative lesion by RNS. Several studies have demonstrated that 8-nitroguanine is not detected in normal tissues but is mostly found in the nucleus of inflammatory cells and/or epithelial cells in inflamed tissues, indicating that 8-nitroguanine may serve as a potential biomarker for nitrative DNA damage induced by RNS in inflamed tissues [45-47]. Recent findings of 8-nitroguanine at the sites of carcinogenesis under various inflammatory conditions in animals and humans imply that the excess generation of RNS may be a risk factor for cancer development in patients suffering from inflammation-related diseases [46, 48, 49].

Several methods have been developed for measurement of 8-nitroguanine *in vivo*, such as HPLC with electrochemical detection, HPLC with a UV detector, GC-MS, and immunohistochemistry. However, their reproducibility and validity have not been well verified [37, 44]. Recently, Sawa *et al.* first reported a sensitive method to quantitate 8-nitroguanine in human urine using immunoaffinity columns with an anti-8-nitroguanine antibody, followed by HPLC-ECD [50]. They found that cigarette smoking is associated with elevated urinary levels of 8-nitroguanine.

Biomarkers of Lipid Oxidation

Malonaldehyde. Malonaldehyde (MDA) (Fig. 1) is one of the end products of lipid peroxidation in the cell membranes or in low-density lipoproteins (LDL) [1]. Levels of MDA are often measured spectrophotometrically by the thiobarbituric acid-reacting substance (TBARS) assay. This simple assay is the most frequently used method in lipid peroxidation research, but some scientists question its clinical utility. Because some aldehydes other than MDA can also be generated in peroxidizing lipid and have the same range of absorbance as MDA, the TBARS assay can be confounded by these chromogens [1]. The HPLC-based TBARS assay can separate MDA from other aldehydes and is suggested as a useful method for examining large numbers of biological samples for lipid peroxidation [1]. The GC-MS method has been used to analyze the end-products of peroxide breakdown such as MDA in human plasma [51]. Peroxides and aldehydes from food can be absorbed via the gut and can affect the determination of the MDA, especially in urine [52].

The results of a recent three-year longitudinal study suggest that serum levels of TBARS (measured by reverse-phase HPLC and spectrophotometric approaches) are strongly predictive of cardiovascular events in patients with stable coronary artery disease, independent of some risk factors (age, low-density lipoprotein, high-density lipoprotein, total cholesterol, triglyceride, BMI, and blood pressure) and inflammatory markers (C-reactive protein, soluble intercellular adhesion molecule-1, interleukin-6) [53].

F_2-Isoprostanes. F_2-Isoprostanes, especially 8-iso-$PGF_{2\alpha}$ (Fig.1), have been proposed as specific, reliable, and non-invasive markers of lipid peroxidation *in vivo* [52, 54]. F_2-Isoprostanes are a group of bioactive prostaglandin-like compounds generated via a non-enzymatic mechanism involving the free radical-initiated peroxidation of arachidonic acid *in vivo*, and they can be measured in most of the biological fluids, among which plasma and urine are the most commonly used samples. The short half-life of F_2-Isoprostanes in plasma limits their practical use, but this is not the case in urine [6]. F_2-Isoprostanes can also be detected in exhaled breath condensate and induced sputum. The MS techniques (GC-MS, GC- MS/MS, LC-MS, LC-MS/MS) can accurately and sensitively measure F_2-Isoprostanes in biological samples [52]. Immunoassays {ELISA, radio immuno assays (RIA)} are also frequently used techniques to quantify

F_2-Isoprostanes because of their low cost and ease of use, although there is limited information on their precision and accuracy [54]. F_2-Isoprostanes are stable in isolated samples, and the samples should be stored at −70 °C to prevent artifactual formation of isoprostanes products [6]. Unlike MDA, the levels of F_2-Isoprostanes are not influenced by lipid content in the diet [55].

F_2-Isoprostanes can also be detected in normal human biological fluids and tissues [54]. The increased levels of 8-iso-$PGF_{2\alpha}$ in plasma, tissue, and urine have been found in many human disorders and have been suggested to play a causative role in oxidative damage in diseases like cardiovascular disease, allergic asthma, hepatic cirrhosis, scleroderma, and Alzheimer's disease [54, 56].

Oxidative Modification of Sugars

Advanced glycation end-products (AGEs) are products of non-enzymatic glycation of proteins by reducing sugars (the Maillard reaction). It has been reported that AGEs accumulate in plasma and tissues with age, diabetes, renal failure, and Alzheimer's disease [1, 57, 58], and they have been considered potentially useful biomarkers for monitoring glycemic control, predicting the risk of diabetes-associated clinical complications, and monitoring the treatment effect of diabetic patients with retinopathy, nephropathy, and neuropathy [57].

Carboxymethyllysine (CML) and pentosidine (Fig. 1) are products of oxidation-accompanied glycation and have been regarded as representative biomarkers of AGEs [56]. In comparison with healthy subjects, serum levels of CML and pentosidine are about 3- and 10-fold higher in diabetic patients with decreased renal function, respectively [60, 61], and the serum levels of AGEs increase with the severity of glomerular lesions in patients with diabetic nephropathy [62] and with the severity of diabetic retinopathy [63]. These findings suggest that AGEs may be a clinically useful tool for assessing diabetic complications. A recent population-based 18-year follow-up study also showed that serum levels of AGEs could predict mortality from cardiovascular disease and coronary heart disease in nondiabetic women [64].

HPLC, GC-MS, ELISA, and immunohistochemistry are commonly used methods for analysis of AGEs. The accuracy and reproducibility of these techniques have not been well examined because there is no universally established unit of measurement for comparing study findings from different laboratories [59, 65]. In addition, confounding factors such as food and tobacco smoke can affect the level of AGE precursors in the body [66, 67].

The Integration of Biomarkers with Epidemiology

Many biomarkers have been developed for the identification of oxidative/nitrosative damage to DNA, proteins, lipids, and sugars in biological samples. Whether these biomarkers are truly useful in the early detection and prevention of diseases requires further validation via human field investigations. There has been a growth in application of biomarkers to epidemiological studies. Such an integrated approach has resulted in a new discipline, molecular epidemiology, which may provide specific information concerning the causal relation of biomarkers with disease outcomes in a population level, ultimately contributing to the development of strategies for health risk assessment and disease prevention [5, 68, 69].

In the literature, a cross-sectional study design has been commonly employed to examine the relation between biomarkers of oxidative/nitrosative stress and diseases. Cross-sectional studies can be easily and rapidly accomplished, but they can only provide information on the association between the biomarkers and some diseases. Whether there are any causal relations between biomarkers and the diseases should be examined by a prospective cohort study [68, 70]. This approach is also the optimum epidemiological study design for biomarker validation, through which the alteration of biomarker values on the course of diseases and the response of biomarkers to the intervention trials could be directly observed, although such a study will require large numbers of participants, an appropriate follow-up period, and high cost. Recently, the use of meta-analysis to re-evaluate published data from many small clinical studies has been considered an efficient approach to obtain information on the effectiveness of intervention trials [5], and a checklist containing specifications for reporting meta-analyses of observational studies (cohort, cross-sectional, and case-control studies, *etc.*) in epidemiology has been

proposed [71].

Application of Biomarkers of Oxidative/ Nitrosative Stress to Intervention Trials

The ultimate goal of developing ideal biomarkers for oxidative/nitrosative damage is to find better tools for the prevention of diseases (Fig. 2). In intervention trials, close monitoring of the alteration of biomarker levels in biological samples may provide important information on which antioxidants and at what dose(s) oxidative/nitrosative damage can be reduced in study subjects with the aim of finding a safe and reliable antioxidant treatment [37, 72]. Many antioxidants from natural products are known to be capable of decreasing oxidative/nitrosative damage *in vitro*, but determining whether they will act the same way *in vivo* will require more convincing evidence from animal and human studies [72-74]. Some studies have demonstrated short-term antioxidant effects against oxidatively/nitrosatively damaged DNA, protein, and lipid peroxidation *in vivo* [41, 74-76], but long-term effects remain to be elucidated.

Several antioxidant interventional trials in humans have showed controversial results, such as the effects of vitamin E on cardiovascular outcomes [77, 78] and of beta-carotene and vitamin A on lung cancer [79], and the reduction by vitamin C supplementation of certain types of oxidative protein damage in subjects with low basal antioxidant but not in those with normal basal level [75]. Moller *et al.* recently have reviewed 139 cross-sectional and intervention studies regarding the effect of antioxidants on oxidatively damaged DNA and have found that many of the studies were "of mediocre value because of problems with design or high baseline DNA damage values" [41]. They also found it impossible to analyze such studies by a meta-analysis because of the great differences in design, biomarkers, and antioxidant supplementation among them. Clearly, the protective effects of antioxidants against human disease still need evidence-based confirmation by well-designed, randomized, controlled epidemiological studies in various study populations.

Conclusions

In the last 2 decades, there has been great progress in the development of biomarkers of oxidative/ nitrosative stress that may eventually be useful in disease prevention. The challenges for the future are (1) to validate available biomarkers for oxidative/ nitrosative damage in animal and human studies based on their specificity, stability for storage, reproducibility, causal relation with disease, and response to antioxidant intervention; (2) to examine the basal levels of oxidative/nitrosative damage in healthy subjects; and (3) to assess the long-term effect of antioxidants on oxidative/nitrosative damage by well-designed, randomized, controlled trials in humans and as well as to examine the consistency of the findings among various studies. The biomarkers of oxidative/ nitrosative damage, if validated, may open the way for



Fig. 2 Potentialities of oxidative/nitrosative stress-related biomarkers for disease prevention.

the development of early detection and prevention strategies for oxidative/nitrosative stress-associated human diseases.

References

1. Halliwell B and Gutteridge JMC: Oxidative stress; in Free radicals in biology and medicine, Halliwell B and Gutteridge JMC eds, 3 rd Ed, Oxford University Press, Oxford University Press, New York (1999) pp 246–350.
2. Sies H: Oxidative stress: from basic research to clinical application. Am J Med (1991) 91: 31S–38S.
3. Cutler RG, Plummer J, Chowdhury K and Heward C: Oxidative stress profiling: part II. Theory, technology, and practice. Ann N Y Acad Sci (2005) 1055: 136–158.
4. Committee on Biological Markers of the National Research Council: Biological markers in environmental health research. Environ Health Perspect (1987) 74: 3–9.
5. Bonassi S and Au WW: Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res (2002) 511: 73–86.
6. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Poulsen H, Verhagen H and Astley SB: Biomarkers. Mol Aspects Med (2002) 23: 101–208.
7. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R and Milzani A: Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med (2006) 10: 389–406.
8. Berlett BS and Stadman ER: Protein oxidation in aging, disease, and oxidative stress. J Biol Chem (1997) 272: 20313–20316.
9. Levine RL: Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med (2002) 32: 790–796.
10. Gieseg S, Duggan S and Gebicki JM: Peroxidation of proteins before lipids in U937 cells exposed to peroxyl radicals. Biochem J (2000) 350: 215–218.
11. Stadtman ER and Levine RL: Protein oxidation. Ann NY Acad Sci (2000) 899: 191–208.
12. Du J and Gebicki JM: Proteins are major initial cell targets of hydroxyl free radicals (2004) 36: 2334–2343.
13. Shacter E: Quantification and significance of protein oxidation in biological samples. Drug Metab Rev (2000) 32: 307–326.
14. Beal MF: Oxidatively modified proteins in aging and disease. Free Radic Biol Med (2002) 32: 797–803.
15. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA and Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int (2004) 65: 1009–1016.
16. Renke J, Popadiuk S, Korzon M, Bugajczyk B and Wozniak M: Protein carbonyl groups' content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis. Free Radic Biol Med (2000) 29: 101–104.
17. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N and Grune T: Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med (1999) 27: 1080–1086.
18. Stadtman ER and Levine RL: Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids (2003) 25: 207–218.
19. Dalle-Donne I, Rossi R, Giustarini D, Milzani A and Colombo R: Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta (2003) 329: 23–38.
20. Choi J, Malakowsky CA, Talent JM, Conrad CC and Gracy RW: Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun (2002) 293: 1566–1570.
21. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR and Butterfield DA: Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: Anapproach to understand pathological and biochemical alterations in AD. Neurobiol Aging (2006) 27:1564–1576.
22. Halliwell B: What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett (1997) 411: 157–160.
23. Bo S, Gambino R, Guidi S, Silli B, Gentile L, Cassader M and Pagano GF: Plasma nitrotyrosine levels, antioxidant vitamins and hyperglycaemia. Diabetic Med (2005) 22: 1185–1189.
24. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr., Penn MS, Sprecher DL, Vita JA and Hazen SL: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA (2003) 289: 1675–1680.
25. Fenster CP, Darley-Usmar VM, Landar AL, Gower BA, Weinsier RL, Hunter GR and Patel RP: Weight Loss and Race Modulate Nitric Oxide Metabolism in Overweight Women. Free Radic Biol Med (2004) 37: 695–702.
26. Duncan MW: A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids (2003) 25: 351–361.
27. Tsikas D and Caidahl K: Recent methodological advances in the mass spectrometric analysis of free and protein-associated 3-nitrotyrosine in human plasma. J Chromatogr B (2005) 814: 1–9.
28. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, Crabb JW and Stuehr DJ: Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci USA (2001) 98: 12056–12061.
29. Turko IV, Li L, Aulak KS, Stuehr DJ, Chang JY and Murad F: Protein tyrosine nitration in the mitochondria from diabetic mouse heart. J Biol Chem (2003) 278: 33972–33977.
30. Elfering SL, Haynes VL, Traaseth NJ, Ettl A and Giulivi C: Aspects, mechanism, and biological relevance of mitochondrial protein nitration sustained by mitochondrial nitric oxide synthase. Am J Physiol Heart Circ Physiol (2004) 286: H22–H29.
31. Kanski J, Behring A, Pelling J and Schoneich C: Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am J Physiol Heart Circ Physiol (2005) 288: H371–H381.
32. Kanski J, Hong SJ and Schoneich C: Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem (2005) 280: 24261–24266.
33. Granger CB, Van Eyk JE, Mockrin SC and Anderson NL: National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation (2004) 109: 1697–1703.
35. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, Miura A, Nagase S, Sakuragi S, Kusano KF, Matsubara H and Ohe T: Elevated Levels of Oxidative DNA Damage in Serum and Myocardium of Patients With Heart Failure. Circ J (2006) 70: 1001–1005.
36. Sato S, Mizuno Y and Hattori N: Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology (2005) 64: 1081–1083.
37. Halliwell B and Whiteman M: Measuring reactive species and oxi-

dative damage *in vivo* and in cell culture: how should you do it and what do the results mean? Br J Pharmacol (2004) 142: 231–255.
38. Collins AR, Cadet J, Moller L, Poulsen HE and Vina J: Are we sure we know how to measure 8-oxo-7,8-dihydroguanine in DNA from human cells? Arch Biochem Biophys (2004) 423: 57–65.
39. Hu CW, Wu MT, Chao MR, Pan CH, Wang CJ, Swenberg JA and Wu KY: Comparison of analyses of urinary 8-hydroxy-2-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun Mass Spectrom (2004) 18: 505–510.
40. Kimura S, Yamauchi H, Hibino Y, Iwamoto M, Sera K and Ogino K: Evaluation of urinary 8-hydroxydeoxyguanine in healthy Japanese people. Basic Clin Pharmacol Toxicol (2006) 98: 496–502.
41. Moller P and Loft S: Dietary antioxidants and beneficial effect on oxidatively damaged DNA. Free Radic Biol Med (2006) 41: 388–415.
42. Gackowski D, Rozalski R, Roszkowski K, Jawien A, Foksinski M and Olinski R: 8-Oxo-7,8-dihydroguanine and 8-oxo-7,8-dihydro-2'-deoxyguanosine levels in human urine do not depend on diet. Free Radic Res (2001) 35: 825–832.
43. Park EM, Shigenaga MK, Degan P, Korn TS, Kitzler JW, Wehr CM, Kolachana P and Ames BN: Assay of excised oxidative DNA lesions: isolation of 8-oxoguanine and its nucleoside derivatives from biological fluids with a monoclonal antibody column. Proc Natl Acad Sci USA (1992) 89: 3375–3379.
44. Ohshima H, Sawa T and Akaike T: 8-nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species: formation, occurrence, and implications in inflammation and carcinogenesis. Antioxid Redox Signal (2006) 8: 1033–1045.
45. Akaike T, Okamoto S, Sawa T, Yoshitake J, Tamura F, Ichimori K, Miyazaki K, Sasamoto K and Maeda H: 8-nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc Natl Acad Sci USA (2003) 100: 685–690.
46. Ma N, Adachi Y, Hiraku Y, Horiki N, Horiike S, Imoto I, Pinlaor S, Murata M, Semba R and Kawanishi S: Accumulation of 8-nitroguanine in human gastric epithelium induced by *Helicobacter pylori* infection, Biochem Biophys Res Commun (2004) 319: 506–510.
47. Horiike S, Kawanishi S, Kaito M, Ma N, Tanaka H, Fujita N, Iwasa M, Kobayashi Y, Hiraku Y, Oikawa S, Murata M, Wang J, Semba R, Watanabe S and Adachi Y: Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J Hepatol (2005) 43: 403–410.
48. Pinlaor S, Ma N, Hiraku Y, Yongvanit P, Semba R, Oikawa S, Murata M, Sripa B, Sithithaworn P and Kawanishi S: Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2'-deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis (2004) 25: 1535–1542.
49. Ma N, Tagawa T, Hiraku Y, Murata M, Ding X and Kawanishi S: 8-Nitroguanine formation in oral leukoplakia, a premalignant lesion. Nitric Oxide (2006) 14: 137–143.
50. Sawa T, Tatemichi M, Akaike T, Barbin A and Ohshima H: Analysis of urinary 8-nitroguanine, a marker of nitrative nucleic acid damage, by high-performance liquid chromatography-electrochemical detection coupled with immunoaffinity purification: association with cigarette smoking. Free Radic Biol Med (2006) 40: 711–720.
51. Yeo HC, Helbock HJ, Chyu DW and Ames BN: Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem (1994) 220: 391–396.
52. Halliwell B: Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res (2000) 47: 410–418.
53. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J and Mason RP: Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease. J Am Coll Cardiol (2004) 44: 1996–2002.
54. Milne GL, Musiek ES and Morrow JD: F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers (2005) Suppl 1: S10–23.
55. Gopaul NK, Halliwell B and Anggard EE: Measurement of plasma F2- isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radic Res (2000) 33: 115–127.
56. Montuschi P, Barnes PJ and Roberts LJ: Isoprostanes: markers and mediators of oxidative stress. FASEB J (2004) 18: 1791–1800.
57. Wu JT: Advanced glycosylation end products: a new disease marker for diabetes and aging. J Clin Lab Anal (1993) 7:252–255.
58. Miyata T, Maeda K, Kurokawa K and van Ypersele de Strihou C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant (1997) 12: 255–258.
59. Singh R, Barden A, Mori T and Beilin L: Advanced glycation end-products: a review. Diabetologia (2001) 44: 129–146.
60. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP and Baynes JW: Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int (1997) 52:1064–1067.
61. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C and Maeda K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol (1996) 7: 1198–1206.
62. Kanauchi M, Nishioka H and Dohi K: Serum levels of advanced glycosylation end products in diabetic nephropathy. Nephron (2001) 89: 228–230.
63. Koga K, Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M and Makita Z: Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res (2002) 22: 13–17.
64. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF and Laakso M: High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men. Arteriosclerosis, Thrombosis, and Vascular Biology (2005) 25: 815–820.
65. Mitushashi T, Vlassara H, Founds HW and Li YM: Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods (1997) 207: 79–88.
66. Koschinski T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K and Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA (1997) 94: 6474–6479.
67. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R and Cerami A: Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA (1997) 94: 13915–13920.

68. Albertini RJ: Biomarker responses in human populations: towards a worldwide map. Mutat Res (1999) 428: 217–226.
69. Merlo DF, Sormani MP and Bruzzi P: Molecular epidemiology: New rules for new tools? Mutat Res (2006) 600: 3–11.
70. Bonassi S, Neri M and Puntoni R: Validation of biomarkers as early predictors of disease. Mutat Res (2001) 480–481: 349–358.
71. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 283: 2008–2012.
72. Halliwell B: Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev (1999) 57: 104–113.
73. Halliwell B, Rafter J and Jenner A: Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr (2005) 81(Suppl 1): 268S–276S.
74. Lee CYJ, Isaac HB, Wang H, Huang SH, Long LH, Jenner AM, Kelly RP and Halliwell B: Cautions in the use of biomarkers of oxidative damage; the vascular and antioxidant effects of dark soy sauce in humans. Biochem Biophys Res Commun (2006) 344: 906–911.
75. Carty JL, Bevan R, Waller H, Mistry N, Cooke M, Lunec J and Griffiths HR: The Effects of Vitamin C Supplementation on Protein Oxidation in Healthy Volunteers. Biochem Biophys Res Commun (2000) 273: 729–735.
76. Mullan BA, Young IS, Fee H and McCance DR: Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension (2002) 40: 804–809.
77. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico): Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet (1999) 354: 447–455.
78. Yusuf S, Dagenais G, Pogue J, Bosch J and Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 342: 154–160.
79. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA and Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst (1996) 88: 1550–1559.